Walgreens Boots Alliance (WBA) reported $38.99 billion in revenue for the quarter ended May 2025, representing a year-over-year increase of 7.3%. EPS of $0.38 for the same period compares to $0.63 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $36.61 billion, representing a surprise of +6.49%. The company delivered an EPS surprise of +11.76%, with the consensus EPS estimate being $0.34.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Walgreens performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- U.S. Retail Pharmacy: $30.72 billion compared to the $28.76 billion average estimate based on four analysts. The reported number represents a change of +7.8% year over year.
- Revenues- U.S. Healthcare: $2.10 billion versus $2.17 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -1.1% change.
- Revenues- International: $6.17 billion versus the four-analyst average estimate of $5.74 billion. The reported number represents a year-over-year change of +7.8%.
- Adjusted operating income (loss)- U.S. Retail Pharmacy: $350 million versus the two-analyst average estimate of $113.67 million.
- Adjusted operating income (loss)- Corporate and Other: -$60 million versus the two-analyst average estimate of -$52.50 million.
- Adjusted operating income (loss)- U.S. Healthcare: $54 million versus the two-analyst average estimate of $72.85 million.
- Adjusted operating income (loss)- International: $214 million versus $196.39 million estimated by two analysts on average.
View all Key Company Metrics for Walgreens here>>>
Shares of Walgreens have returned +1.1% over the past month versus the Zacks S&P 500 composite's +5.1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
